Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 740 (ZNF740) is a transcription factor belonging to the Krueppel C2H2-type zinc finger family, involved in sequence-specific DNA binding and transcriptional regulation[3][4]. In cancer biology, ZNF740 is upregulated in hepatocellular carcinoma, where it promotes cell proliferation, migration, and invasion via the METTL3/HIF1A signaling axis and regulates epigenetic RNA modification[1]. In acute myeloid leukemia, ZNF740 is a critical determinant of sensitivity to the BCL-2 inhibitor venetoclax by regulating the transcription of the pro-apoptotic gene NOXA, thereby influencing apoptotic responses and mediating therapeutic resistance or sensitivity. Its expression is associated with various disease states, including cancer and cardiovascular disease via NPPA gene regulation[1][2][4].
Regulation of sensitivity to venetoclax by activating the pro-apoptotic gene PMAIP1 (NOXA), which influences MCL-1 protein levels and apoptotic priming in AML cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 740 (ZNF740).